

Driving vaccine R&D towards global public health and health equity: RIGHT foundation's approach

Hani Kim, PhD, MPH

Executive Director

RIGHT (Research Investment for Global Health Technology) foundation

March 29th, 2022




RIGHT
국제보건기술연구기금


RIGHT Foundation: What & Why?

- Korean public private partnership dedicated to funding R&D for impact on global public health
- Leverages the Korean Ministry of Health and Welfare's Overseas Development Assistance (ODA)
- **Intent:** Engage Korean life science partners to develop critical health technologies as *global public good*

**Fund at establishment
2018 - 2023**



Committed funding until 2026



- ~ US\$ 97 million anticipated for the 2nd investment cycle (2023 – 2028)

INDUSTRY PARTNERS




INDUSTRY PARTNERS



What guides us to develop critical health technologies as global public good?

Seven Strategic Priorities and Four Core Principles of Immunization Agenda 2030



- Think equitable access from the start (e.g. target use-case, product characteristics)
- Learn *from* and *with* local stakeholders
- Learn the context (e.g. end users' needs and perspectives)
- Plan for integration into the local public health system
- Engage the key stakeholders early (e.g. end-users, local governments, regulatory authorities, global procuring agencies)



³ Source: WHO Immunization Agenda 2030 at <https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030>

What do we strive for?

MISSION: Alleviate the burden of infectious diseases that disproportionately affect the people in the low- and middle-income countries

	#1 Product Development	#2 Collaboration	#3 Evidence Generation	#4 Training
STRATEGIC OBJECTIVES	<p>Develop essential health technologies as global public good</p> <ul style="list-style-type: none">▪ Aim for public procurement▪ Ensure global access▪ Support technology transfer to enable local production	<p>Catalyze international Collaboration</p> <ul style="list-style-type: none">▪ Foster an exchange of knowledge and skills (i.e. co-develop)▪ Leverage Korea's strengths (e.g. process optimization, engineering)	<p>Strengthen evidence base reflecting the LMIC context</p> <ul style="list-style-type: none">▪ Learn to reflect the needs <i>of</i> the LMICs <i>with</i> LMIC partners▪ Let the local context guide the target use case & product characteristics from the start	<p>Train work force in manufacturing essential health technologies</p> <ul style="list-style-type: none">▪ Support regional-level self-sufficiency in developing essential public health technologies (e.g. vaccines, biologics, diagnostics)

What have we accomplished so far?



- ~US\$45M committed to support **45** grants
- Engaged **50** Korean institutions in global health R&D, with **18** international partners
- >15 disease types targeted associated with ~92.8 million DALYs in low-income countries (IHME Global Burden of Diseases 2019)

We require commitment to global access

Supply

- Commitment to ensure sufficient supply of the funded products to LMICs


Pricing

- Commitment to set affordable prices for *public procurement* in the World Bank-defined low-income countries (LICs), and tiered pricing for middle income countries (MICs).

License

- If the grantee decides not to supply to the LMICs, commitment to grant royalty-free, non-exclusive licenses to users operating for the benefit of the public market in LMICs.

We anticipate seven products to achieve WHO PQ by 2028



G6PD, Glucose 6 phosphate dehydrogenase; POCT – Point-of-Care test; TB – tuberculosis; HepA – Hepatitis A; LAM - Lipoarabinomannan

Key considerations for engaging partners in R&D global access:

- High quality data on market demand (i.e. procurement mechanism, policies to support adoption)
- High quality data on the market share by suppliers (i.e. competitive landscape, supply security)
- Strategies to access the private and public market
- Strategic alignment on global access and commitment to public health

Acknowledgements



BILL & MELINDA
GATES foundation

KOREAN COMPANIES

Full
Partners:



Associate
Partners:



감사합니다

Thank you



RIGHT
국제보건기술연구기금